MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
09. Mai 2022 07:00 ET
|
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab Higher rates of complete skin clearance were...